Immunohistochemical analysis of CD30-positive lymphoproliferative disorders for expression of CD95 and CD95L

Modern Pathology

Volumn 13, Issue 4, 2000, Pages 446-451

  Sigel, Jessica E ^a   Hsi, Eric D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anaplastic large cell lymphoma; CD30; CD95 Fas; CD95L FasL; Lymphomatoid papulosis

Indexed keywords

CD30 ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ANAPLASTIC CARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SKIN LYMPHOMA;

EID: 0033995855     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880076     Document Type: Article

References (31)

1. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, et al. CD30/Ki-l-positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995;13:1343-54.
2. Beljaards RC, Meijer CJ, Scheffer E, Toonstra J, van Vloten WAX vander Putte SC, et al. Prognostic significance of CD30 (Ki-l/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin: a clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989;135: 11169-78.
3. Tomaszewski MM, Lupton GP, Krishnan J, May DL. A comparison of clinical, morphological and immunohistochemical features of lymphomatoid papulosis and primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma. I Cutan Pathol 1995:22:310-8.
4. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-l)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993;28:973-80.
5. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997:90:354-71.
6. Bernier M, Bagot M, Broyer M, Parcel JP, Gaulard P, Wechsler J. Distinctive clinicopathologic features associated with regressive primary CD30 positive cutaneous lymphomas: analysis of 6 cases. J Cutan Pathol 1997;24:157-63.
7. Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer 1993:71:2097-104.
8. de Bruin PC, Beljaards RC, van Heerde P, Van Der Valk P, Noorduyn LA, Van Krieken JH, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology 1993:23:127-35.
9. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity - a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 1997; 21:1420-32.
10. Beylot-Barry M, Lamant L, Vergier B, de Muret A, Fraitag S, Delord B, etal. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol 1996:149: 483-92.
11. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996:87:3437-41.
12. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993:75:1169-78.
13. Nagata S, Golstein P. The Fas death factor. Science 1995:267: 1449-56.
14. Nagata S. Fas ligand and immune evasion. Nature Med 1996:2:1306-7.
15. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, etal Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993:69:415-29.
16. Dirks W, Schone S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. Br J Haematol 1997; 96:584-93.
17. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995:16:569-74.
18. Nagata S, Suda T. Fas and Fas ligand: Ipr and gld mutations. Immunol Today 1995:16:39-43.
19. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995:268:1347-9.
20. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995:81:935-46.
21. Paulli M, Berti E, Boveri E, Kindl S, Bonoldi E, Gambirii C, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcI-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998:29:1223-30.
22. Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997:133:829-33.
23. Chott A, Kaserer K, Augustin I, Vesely M, Heinz R, Oehlinger W, et al. Ki-1-positive large cell lymphoma: a clinicopathologic study of 41 cases. Am J Surg Pathol 1990:14:439-48.
24. Kinney MC, Collins RD, Greer JP, VVhitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993;17:85968.
25. Nguyen PL, Harris NL, Ritz J, Robertson MJ. Expression of CD95 antigen and bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol 1996;148:847-53.
26. Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, Smoller BR, et al. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease. Blood 1996;88: 1765-70.
27. NPM/ALK: a distinct clinicopathologic entity. Blood 1995:86:1954-60.
28. Mullauer L, Mosberger I, Chott A. Fas ligand expression in nodal non-Hodgkin's lymphoma. Mod Pathol 1998;11:36975.
29. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nature Med 1998;4:31-6.
30. Xerri L, Carbuccia N, Pare P, Hassoun J, Birg F. Frequent expression of FAS/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 1995:27:235-41.
31. Plumas J, Jacob MC, Chaperot L, Chaperot L, Molens JP, Sotto JJ, et al. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-l)-mediated apoptosis. Blood 1998:91:2875-85.